# QuantifyHER

Source: https://onco.cc/trials/nct06551116/  
OnCo record `nct06551116` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

QuantifyHER evaluates more precise ways to measure HER2 in tumors. It asks whether these measurements help distinguish people who respond to trastuzumab deruxtecan from those who do not.

## Summary

QuantifyHER evaluates more precise ways to measure HER2 in tumors. It asks whether these measurements help distinguish people who respond to trastuzumab deruxtecan from those who do not.

Observational study registered as NCT06551116, sponsored by Abramson Cancer Center at Penn Medicine. Registry enrollment is 200 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
- Tags: ucsf-breast-coverage; observational
- Registry id: NCT06551116
- Phase: observational
- Setting: HER2-low metastatic breast cancer receiving trastuzumab deruxtecan
- Sponsor: Abramson Cancer Center at Penn Medicine

## Sources

- ClinicalTrials.gov NCT06551116: https://clinicaltrials.gov/study/NCT06551116
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT06551116

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct06551116.json